+

MX2021013943A - Pautas posologicas para la administracion de un anticuerpo biespecifico frente a lag-3/pd-l1. - Google Patents

Pautas posologicas para la administracion de un anticuerpo biespecifico frente a lag-3/pd-l1.

Info

Publication number
MX2021013943A
MX2021013943A MX2021013943A MX2021013943A MX2021013943A MX 2021013943 A MX2021013943 A MX 2021013943A MX 2021013943 A MX2021013943 A MX 2021013943A MX 2021013943 A MX2021013943 A MX 2021013943A MX 2021013943 A MX2021013943 A MX 2021013943A
Authority
MX
Mexico
Prior art keywords
lag
administration
dosage regimes
bispecific antibody
regimes
Prior art date
Application number
MX2021013943A
Other languages
English (en)
Inventor
Michelle Morrow
Fiona Germaschewski
Daniel Gliddon
Kin-Mei Leung
Cristian Gradinaru
Christopher Shepherd
Josefin-Beate Holz
Louis Kayitalire
Original Assignee
F Star Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1906807.1A external-priority patent/GB201906807D0/en
Priority claimed from GB201914040A external-priority patent/GB201914040D0/en
Priority claimed from GBGB2000318.2A external-priority patent/GB202000318D0/en
Application filed by F Star Therapeutics Ltd filed Critical F Star Therapeutics Ltd
Publication of MX2021013943A publication Critical patent/MX2021013943A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La solicitud se refiere a pautas posológicas para la administración de una molécula de anticuerpo que se une al ligando 1 de muerte programada (PD-L1) y al gen 3 de activación de linfocitos (LAG-3) y a su uso médico en el tratamiento del cáncer en pacientes humanos.
MX2021013943A 2019-05-14 2020-05-14 Pautas posologicas para la administracion de un anticuerpo biespecifico frente a lag-3/pd-l1. MX2021013943A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1906807.1A GB201906807D0 (en) 2019-05-14 2019-05-14 Dosages regimes for the administration of lag-3/pd-l1 bispectic antibody
GB201914040A GB201914040D0 (en) 2019-09-30 2019-09-30 Dosage regimes for the administration of lag-3/pd-l1 bispecific antibody
GBGB2000318.2A GB202000318D0 (en) 2020-01-09 2020-01-09 Dosage regimes for the administration of LAG-3/PD-L1 bispecific antibody
PCT/EP2020/063529 WO2020229626A1 (en) 2019-05-14 2020-05-14 Dosage regimes for the administration of a lag-3/pd-l1 bispecific antibody

Publications (1)

Publication Number Publication Date
MX2021013943A true MX2021013943A (es) 2022-01-04

Family

ID=70775359

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013943A MX2021013943A (es) 2019-05-14 2020-05-14 Pautas posologicas para la administracion de un anticuerpo biespecifico frente a lag-3/pd-l1.

Country Status (12)

Country Link
US (1) US20220275092A1 (es)
EP (1) EP3969477A1 (es)
JP (1) JP2022533578A (es)
KR (1) KR20220008316A (es)
CN (1) CN114206939A (es)
AU (1) AU2020275209A1 (es)
BR (1) BR112021022831A2 (es)
CA (1) CA3139003A1 (es)
IL (1) IL287979A (es)
MX (1) MX2021013943A (es)
SG (1) SG11202112136RA (es)
WO (1) WO2020229626A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109311993B (zh) 2016-06-20 2022-12-20 F-星治疗有限公司 Lag-3结合元件
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
JP7360440B2 (ja) 2018-07-12 2023-10-12 エフ－スター セラピューティクス リミテッド Ｐｄ－ｌ１及びｃｄ１３７に結合する抗体分子
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
WO2020011966A1 (en) 2018-07-12 2020-01-16 F-Star Beta Limited Antibody molecules that bind cd137 and ox40
PH12023552704A1 (en) * 2021-03-31 2024-02-19 Merus Nv Novel multispecific antibodies
GB202304278D0 (en) 2023-03-23 2023-05-10 F Star Therapeutics Ltd Dosage regimens for the administration of a bispecific antibody in combination with chemotherapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3472207T1 (sl) 2016-06-20 2021-04-30 F-Star Delta Limited Vezavne molekule, ki vežejo PD-L1 in LAG-3
BR112019018759A2 (pt) * 2017-05-30 2020-05-05 Bristol-Myers Squibb Company composições compreendendo uma combinação de um anticorpo anti-lag-3, um inibidor da via pd-1, e um agente imunoterápico
DK3631454T3 (da) * 2017-05-30 2023-12-04 Bristol Myers Squibb Co Behandling af lag-3 positive tumorer

Also Published As

Publication number Publication date
CA3139003A1 (en) 2020-11-19
US20220275092A1 (en) 2022-09-01
JP2022533578A (ja) 2022-07-25
CN114206939A (zh) 2022-03-18
KR20220008316A (ko) 2022-01-20
BR112021022831A2 (pt) 2022-01-18
IL287979A (en) 2022-01-01
AU2020275209A1 (en) 2021-12-23
EP3969477A1 (en) 2022-03-23
WO2020229626A1 (en) 2020-11-19
SG11202112136RA (en) 2021-11-29

Similar Documents

Publication Publication Date Title
MX2021013943A (es) Pautas posologicas para la administracion de un anticuerpo biespecifico frente a lag-3/pd-l1.
MX2024007356A (es) Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y metodos para su uso.
MX2018011054A (es) Metodos para tratar cancer de mama er+, her2-, hrg+ usando terapias de combinacion que comprenden un anticuerpo anti-erbb3.
MY198928A (en) B7-h3 antibody, antigen-binding fragment thereof and medical use thereof
SA520420109B1 (ar) أجسام مضادة
SG170730A1 (en) Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
PH12022551960A1 (en) Antibodies binding to b7h4
MX2021001143A (es) Anticuerpo de union a il-4r humana, fragmento de union a antigeno y uso medico del mismo.
Mannas et al. Long-term treatment with temozolomide in malignant glioma
MX2020010119A (es) Anticuerpo anti-cd27, fragmento de union a antigeno del mismo y uso medico del mismo.
Morris et al. Results of a 5-week schedule of modern total skin electron beam radiation therapy
MX2023006419A (es) Compuestos polipéptidos modificados con lactama.
PH12023550032A1 (en) Tubulysins and protein-tubulysin conjugates
MX2023007178A (es) Complejo de anticuerpo anti-il-4r o fragmento de enlace a antigeno y uso medico del mismo.
Awidi et al. Generic imatinib therapy among Jordanians: an observational assessment of efficacy and safety in routine clinical practice
PH12021551174A1 (en) Novel folr1 specific binding proteins for cancer diagnosis and treatment
MX2024007749A (es) Formulaciones clinicas de anticuerpos anti-tigit.
Balermpas et al. Concomitant chemoradiotherapy versus induction chemotherapy followed by chemoradiotherapy as definitive, first line treatment of squamous cell carcinoma of the head and neck: a retrospective single center analysis
MX2021005266A (es) Regimen de dosificacion del anticuerpo anti-gen de activacion de linfocitos 3 (anti-lag3) y terapia combinada con anticuerpo anti-muerte progamada-1 (anti-pd-1) para el tratamiento del cancer.
PH12022551021A1 (en) Sequential anti-cd19 therapy
Lachota et al. Dasatinib effect on NK Cells and anti-tumor immunity
Nagai et al. The preclinical activities of PTC596, a novel tubulin binding agent that down-regulates BMI1, alone and in combination with bortezomib in multiple myeloma
MX2023002278A (es) Uso de un anticuerpo anti-pd-1 y un farmaco antineoplasico citotoxico en el tratamiento del cancer de pulmon no microcitico.
AU2020360413A8 (en) Methods of treating conditions related to the S1P1 receptor
Ibrahim Global initiative to establish and implement dose rounding policy for expensive cancer therapy
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载